Nuvalent

Miels

Biotech

GSK inks $10.6B Nuvalent buyout to challenge Roche and Pfizer

GSK is buying two near-approval therapies that could challenge lung cancer treatments from Roche, Pfizer and other drugmakers.

Nick Paul Taylor Jun 9, 2026 4:41am

next step ladder climb succeed win

Nuvalent races to FDA to challenge Pfizer for lung cancer market

Nov 17, 2025 7:45am

cancer target detection radiopharma radio

Nuvalent trots out strong pivotal data in FDA lung cancer push

Jun 24, 2025 6:30am

Wall Street sign

Nuvalent banks $166M IPO to push resistance-beating cancer drugs

Jul 29, 2021 11:20am

Financial documents next to blocks that spell IPO

Nuvalent newest biotech to file for $100M IPO to fund 2 trials

Jul 7, 2021 2:56pm